Biocon
Biocon Limited, a leading biopharmaceutical company headquartered in Bengaluru, India, has established itself as a key player in the global biotechnology industry since its founding in 1978. With a strong focus on biopharmaceuticals, biosimilars, and novel biologics, Biocon operates across major regions including Asia, Europe, and North America. The company is renowned for its innovative products, particularly in the fields of diabetes, oncology, and autoimmune diseases. Biocon's commitment to affordability and accessibility sets it apart, making significant strides in providing high-quality healthcare solutions. Notable achievements include the launch of India's first biosimilar monoclonal antibody and recognition as a pioneer in the biosimilars market. With a robust pipeline and a reputation for excellence, Biocon continues to shape the future of biotechnology on a global scale.
DitchCarbon Score
How does Biocon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocon's score of 40 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biocon's reported carbon emissions
In 2023, Biocon reported total carbon emissions of approximately 131,095,000 kg CO2e, comprising 31,456,000 kg CO2e from Scope 1 and 31,809,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions accounted for about 67,830,000 kg CO2e. This marked a significant increase from 2022, where total emissions were approximately 71,397,000 kg CO2e, with Scope 1 emissions at 116,989,000 kg CO2e and Scope 2 at 25,307,000 kg CO2e. Biocon has set ambitious climate commitments, aiming for a 20% reduction in Scope 1 and Scope 2 emissions by 2032, having already achieved a 14% reduction from the baseline year of FY 2022. This commitment reflects the company's proactive approach to addressing climate change and reducing its carbon footprint. Overall, Biocon's emissions data and reduction targets illustrate its ongoing efforts to enhance sustainability and mitigate climate impact within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 55,997,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 127,530,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocon is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
